Dynamics and control of measles in Portugal: accessing the impact of anticipating the age for the first dose of MMR from 15 to 12 months of age

Ana Cristina Paulo*, Manuel C. Gomes, M. Gabriela M. Gomes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The all-time low incidence of measles in Portugal in the recent years, raises questions regarding whether the disease has been eliminated, the role of recent control measures, and the epidemiological consequences of the rise in the proportion of newborns to vaccinated mothers, as opposed to those born to mothers who acquired immunity by natural infection. We estimate the vaccination coverage against measles in Portugal on a cohort-by-cohort basis, and incorporate this information into an age-structured seasonally-driven mathematical model aimed at reproducing measles dynamics in the past decades. The model reproduces documented trends in disease notifications and the serological profile of the Portuguese population, as estimated by a recent National Serological Survey. We provide evidence that the effective reproduction number (Re) of measles has been driven below 1 in Portugal, and that sustained measles elimination is crucially dependent upon the maintenance of a high (>95%) coverage with the MMR I vaccine in the future. If the vaccination coverage decreases to levels around 90% the anticipation of the first dose of the MMR I from 15 to 12 months of age, will ensure that Re remains below 1.

Original languageEnglish
Pages (from-to)2418-2427
Number of pages10
JournalVaccine
Volume26
Issue number19
Early online date19 Mar 2008
DOIs
Publication statusPublished - 2 May 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • mathematical modeling
  • measles
  • Portugal
  • vaccination

Fingerprint

Dive into the research topics of 'Dynamics and control of measles in Portugal: accessing the impact of anticipating the age for the first dose of MMR from 15 to 12 months of age'. Together they form a unique fingerprint.

Cite this